As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.
The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
The number of COVID-19 vaccination doses administered per 100 people in Ireland rose to 221 as of Oct 27 2023. This dataset includes a chart with historical data for Ireland Coronavirus Vaccination Rate.
As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.
Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.
This statistic displays the share of children immunized against measles, mumps and rubella(MMR) by 24 months of age in Ireland from 2000 to 2023. In 2001, ** percent of children were vaccinated against MMR, by 2023 this rate had increased to ** percent.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Please see FAQ for latest information on COVID-19 Data Hub Data Flows. https://covid-19.geohive.ie/pages/helpfaqs Category Field label Field Name Explanation
ExtractDate Extract Date Date the data is Extracted
Latitude Latitude
Longitude Longitude
VaccinationDate Vaccination Date Date the Vaccination occurred
Week Week Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/
TotalDailyVaccines Total Daily Vaccines
Gender Male
Female
NA
Dose Number Dose1 Dose 1
Dose2 Dose 2
SingleDose Single Dose
Vaccine Brand Moderna
Pfizer
Janssen
AstraZeneca
Age Group Partial_Age0to9 At Least One Dose Age 0 to 11 Dose 1 of Astrazenenca, MRNA or Single Dose Vaccine
Partial_Age10to19 At Least One Dose Age 12 to 19
Partial_Age20to29 At Least One Dose Age 20 to 29
Partial_Age30to39 At Least One Dose Age 30 to 39
Partial_Age40to49 At Least One Dose Age 40 to 49
Partial_Age50to59 At Least One Dose Age 50 to 59
Partial_Age60to69 At Least One Dose Age 60 to 69
Partial_Age70to79 At Least One Dose Age 70 to 79
Partial_Age80+ At Least One Dose Age80+
Partial_NA At Least One Dose Not Assigned
Age Group Cumulative ParCum_Age0to9 Cumulative Age 0 to 11 Cumulative At least One Dose Age 0 to 11
ParCum_Age10to19 Cumulative Age 12 to 19 Cumulative At least One Dose Age 12 to 19
ParCum_Age20to29 Cumulative Age 20 to 29 Cumulative At least One Dose Age 20 to 29
ParCum_Age30to39 Cumulative Age 30 to 39 Cumulative At least One Dose Age 30 to 39
ParCum_Age40to49 Cumulative Age 40 to 49 Cumulative At least One Dose Age 40 to 49
ParCum_Age50to59 Cumulative Age50 to 59 Cumulative At least One Dose Age 50 to 59
ParCum_Age60to69 Cumulative Age 60 to 69 Cumulative At least One Dose Age 60 to 69
ParCum_Age70to79 Cumulative Age 70 to 79 Cumulative At least One Dose Age 70 to 79
ParCum_80+ Cumulative Age 80+ Cumulative At least One Dose Age 80+
Age Group Cumulative Percent ParCum_NA Cumulative Age Not Assigned Cumulative At least One Dose Age Not Assigned
ParPer_Age0to9 At Least One Dose Percent Age 0 to 11 Cumulative At least One Dose Age cohort/ Age cohort population
ParPer_Age10to19 At Least One Dose Percent Age 12 to 19
ParPer_Age20to29 At Least One Dose Percent Age 20 to 29
ParPer_Age30to39 At Least One Dose Percent Age 30 to 39
ParPer_Age40to49 At Least One Dose Percent Age 40 to 49
ParPer_Age50to59 At Least One Dose Percent Age 50 to 59
ParPer_Age60to69 At Least One Dose Percent Age 60 to 69
ParPer_Age70to79 At Least One Dose Percent Age 70 to 79
ParPer_80+ At Least One Dose Percent 80+
ParPer_NA At Least One Dose Percent Not Assigned
Age Group Fully_Age0to9 Fully vaccinated Age 0 to 11 Dose 2 of An MRNA or AztraZeneca Vaccine or a single dose vaccine of a Janssen
Fully_Age10to19 Fully vaccinated Age 12 to 19
Fully_Age20to29 Fully vaccinated Age 20 to 29
Fully_Age30to39 Fully vaccinated Age 30 to 39
Fully_Age40to49 Fully vaccinated Age 40 to 49
Fully_Age50to59 Fully vaccinated Age 50 to 59
Fully_Age60to69 Fully vaccinated Age 60 to 69
Fully_Age70to79 Fully vaccinated Age 70 to 79
Fully_Age80+ Fully vaccinated Age 80+
Fully_NA Fully vaccinated Age Not Available
Age Group Cumulative FullyCum_Age0to9 Cumulative Fully vaccinated Age 0 to 11
FullyCum_Age10to19 Cumulative Fully vaccinated Age 12 to 19
FullyCum_Age20to29 Cumulative Fully vaccinated Age 20 to 29
FullyCum_Age30to39 Cumulative Fully vaccinated Age 30 to 39
FullyCum_Age40to49 Cumulative Fully vaccinated Age 40 to 49
FullyCum_Age50to59 Cumulative Fully vaccinated Age 50 to 59
FullyCum_Age60to69 Cumulative Fully vaccinated Age 60 to 69
FullyCum_Age70to79 Cumulative Fully vaccinated Age 70 to 79
FullyCum_80+ Cumulative Fully vaccinated Age 80+
Age Group Cumulative Percent FullyCum_NA Cumulative Fully vaccinated Age Not Available
FullyPer_Age0to9 Cumulative Percent Fully vaccinated Age 0 to 11 Cumulative Fully Vaccinated Age cohort/ Age cohort population
FullyPer_Age10to19 Cumulative Percent Fully vaccinated Age 12 to 19
FullyPer_Age20to29 Cumulative Percent Fully vaccinated Age 20 to 29
FullyPer_Age30to39 Cumulative Percent Fully vaccinated Age 30 to 39
FullyPer_Age40to49 Cumulative Percent Fully vaccinated Age 40 to 49
FullyPer_Age50to59 Cumulative Percent Fully vaccinated Age 50 to 59
FullyPer_Age60to69 Cumulative Percent Fully vaccinated Age 60 to 69
FullyPer_Age70to79 Cumulative Percent Fully vaccinated Age 70 to 79
FullyPer_80+ Cumulative Percent Fully vaccinated Age 80+
FullyPer_NA Cumulative Percent Fully vaccinated Age Not Available
In 2022, the immunisation of measles in Ireland remained nearly unchanged at around ** percent of children aged less than one year. But still, the immunisation reached its lowest value of the observation period in 2022. Find more key insights for the immunisation in countries like Denmark, Norway, and Sweden.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Ireland: Percent of children ages 12-23 months with measles immunization: The latest value from 2022 is 90 percent, unchanged from 90 percent in 2021. In comparison, the world average is 84 percent, based on data from 187 countries. Historically, the average for Ireland from 1983 to 2022 is 79 percent. The minimum value, 10 percent, was reached in 1983 while the maximum of 93 percent was recorded in 2013.
This statistic displays the share of children that have received the hepatitis B vaccination by 24 months of age in Ireland from 2010 to 2023. The uptake rate of the hepatitis B vaccination remained fairly consistent over the provided time interval, ** percent of children had been vaccinated by their second birthday in 2023.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Please see FAQ for latest information on COVID-19 Data Hub Data Flows https://covid-19.geohive.ie/pages/helpfaqs Field label Field Name Explanation Formula
ExtractDate Extract Date Date the data is Extracted
Latitude Latitude
Longitude Longitude
VaccinationDate Vaccination Date Date the Vaccination occurred
VaccineText Vaccine Date Text
AdditionalDose First Booster Dose The general population receiving their first booster dose of a vaccine
ImmunoDose Immunocompromised Dose Those who are immunocompromised receiving an extra dose as part of their primary course
AdditionalDoseCum First Booster Dose Cumulative
ImmunoDoseCum Immunocompromised Dose Cumulative
EligiblePop Population Over 5
PerBoosterDose % Population Boosted Percent of population over 5 with a first booster dose (First Booster Dose Cumulative/Population Over 5)*100
AdditionalDose2 Second Booster Dose The general population receiving a Second booster dose
ImmunoDose2 Second Immunocompromised Dose Those who are immunocompromised receiving an extra Immunocompromised dose
AdditionalDoseCum2 Second Booster Cumulative
ImmunoDoseCum2 Second Immunocompromised Dose Cumulative
EligiblePop2 Population Over 5
PerBoosterDose2 % Population Second Booster Percent of population over 5 with a second booster dose (Second Booster Dose Cumulative/Population Over 5)*100
The Cover of Vaccination Evaluated Rapidly programme (COVER) evaluates childhood immunisation in England, collating data for children aged 1, 2 and 5.
Quarterly data tables are provisional and give an indication of current coverage. Data is collected by financial year.
For data since April 2012, see vaccine uptake guidance and the latest coverage data.
For pre-2012 data, see the http://webarchive.nationalarchives.gov.uk/20140629102627/http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1211441442288" class="govuk-link">UK government web archive.
Annual data is more complete: use annual data to look at longer-term trends.
NHS https://digital.nhs.uk/data-and-information" class="govuk-link">Health and Social Care Information Centre publishes annual data for England:
https://digital.nhs.uk/data-and-information/publications/statistical/nhs-immunisation-statistics/nhs-immunisation-statistics-england-2012-13" class="govuk-link">Annual vaccine coverage statistics for England, April 2012 to March 2013
https://digital.nhs.uk/data-and-information/publications/statistical/nhs-immunisation-statistics/nhs-immunisation-statistics-england-2011-12" class="govuk-link">Annual vaccine coverage statistics for England, April 2011 to March 2012
Vaccination coverage data for Scotland, Northern Ireland and Wales:
For any enquiries or feedback, please contact cover@phe.gov.uk.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Ireland: Percent of one-year-old children with Hepatitis B immunization: The latest value from 2022 is 93 percent, unchanged from 93 percent in 2021. In comparison, the world average is 85 percent, based on data from 183 countries. Historically, the average for Ireland from 2010 to 2022 is 91 percent. The minimum value, 46 percent, was reached in 2010 while the maximum of 95 percent was recorded in 2011.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Ireland IE: Immunization: HepB3: % of One-Year-Old Children data was reported at 95.000 % in 2016. This stayed constant from the previous number of 95.000 % for 2015. Ireland IE: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 95.000 % from Dec 2010 (Median) to 2016, with 7 observations. The data reached an all-time high of 95.000 % in 2016 and a record low of 46.000 % in 2010. Ireland IE: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Ireland – Table IE.World Bank: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;
Immunization against DPT of Ireland decreased by 4.30% from 93.0 % in 2022 to 89.0 % in 2023. Since the 1.05% rise in 2013, immunization against DPT dropped by 7.29% in 2023. Child immunization measures the percentage of children ages 12-23 months who received vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Published as part of Health in Ireland: Key Trends 2016 (Department of Health)
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
IntroductionGuidelines for the management of rheumatoid arthritis (RA) recommend using influenza and pneumococcal vaccinations to mitigate infection risk. The level of adherence to these guidelines is not well known in the UK. The aims of this study were to describe the uptake of influenza and pneumococcal vaccinations in patients with RA in the UK, to compare the characteristics of those vaccinated to those not vaccinated and to compare vaccination rates across regions of the UK.MethodsA retrospective cohort study of adults diagnosed with incident RA and treated with non-biologic immunosuppressive therapy, using data from a large primary care database. For the influenza vaccination, patients were considered unvaccinated on 1st September each year and upon vaccination their status changed to vaccinated. For pneumococcal vaccination, patients were considered vaccinated after their first vaccination until the end of follow-up. Patients were stratified by age 65 at the start of follow-up, given differences in vaccination guidelines for the general population.ResultsOverall (N = 15,724), 80% patients received at least one influenza vaccination, and 50% patients received a pneumococcal vaccination, during follow-up (mean 5.3 years). Of those aged below 65 years (N = 9,969), 73% patients had received at least one influenza vaccination, and 43% patients received at least one pneumococcal vaccination. Of those aged over 65 years (N = 5,755), 91% patients received at least one influenza vaccination, and 61% patients had received at least one pneumococcal vaccination. Those vaccinated were older, had more comorbidity and visited the GP more often. Regional differences in vaccination rates were seen with the highest rates in Northern Ireland, and the lowest rates in London.ConclusionsOne in five patients received no influenza vaccinations and one in two patients received no pneumonia vaccine over five years of follow-up. There remains significant scope to improve uptake of vaccinations in patients with RA.
This statistic displays the quarterly uptake rate of the mumps, measles and rubella (MMR) vaccination in Northern Ireland from 2013 to 2023, by age group. In the last quarter of 2023, fewer than 90 percent of children had received the first dose of the MMR vaccination by their second birthday.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Ireland IE: Immunization: DPT: % of Children Aged 12-23 Months data was reported at 95.000 % in 2016. This stayed constant from the previous number of 95.000 % for 2015. Ireland IE: Immunization: DPT: % of Children Aged 12-23 Months data is updated yearly, averaging 83.000 % from Dec 1980 (Median) to 2016, with 37 observations. The data reached an all-time high of 96.000 % in 2014 and a record low of 34.000 % in 1980. Ireland IE: Immunization: DPT: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Ireland – Table IE.World Bank: Health Statistics. Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Ireland IE: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 92.000 % in 2016. This records a decrease from the previous number of 93.000 % for 2015. Ireland IE: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 78.000 % from Dec 1983 (Median) to 2016, with 34 observations. The data reached an all-time high of 93.000 % in 2015 and a record low of 10.000 % in 1984. Ireland IE: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Ireland – Table IE.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;
This statistic displays the share of children that have received the pneumococcal conjugate vaccine (PCV) by 24 months of age in Ireland from 2010 to 2023. In 2023, ** percent of children received the PCV by their second birthday, a slight decrease from the preceding year.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Pairwise comparisons for the Irish (N = 1,030) and UK (N = 2,020) samples.
As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.
The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.